Payment overview · 2025
General Payments
$689.55
26 reported records · 15 companies
Healthcare provider profile · identity verified
Anwar A Khan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OCALA, FL · NPI 1942268578
Verified facts
What the public records show
CMS Open Payments records show Anwar A Khan, MD received $689.55 in general payments during 2025 across 26 reported records.
Abbott Laboratories accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $103.22 | 15.0% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $82.56 | 12.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.25 | 11.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.04 | 10.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.14 | 7.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.07 | 7.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.81 | 5.9% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $40.24 | 5.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $34.60 | 5.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $34.17 | 5.0% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $28.07 | 4.1% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $21.50 | 3.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.70 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.90 | 2.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.28 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $689.55 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $103.22 | 2 | 2025 |
Source payment records
|
|||||
| SCOPIS ENT Normalized: scopis ent |
Device | Stryker Corporation | $82.56 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.04 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.14 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $40.24 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $34.60 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.97 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1168 | 326 |
| Amlodipine Besylate | Amlodipine Besylate | 583 | 173 |
| Lisinopril | Lisinopril | 552 | 164 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 361 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 334 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 89 |
| Omeprazole | Omeprazole | 327 | 102 |
| Losartan Potassium | Losartan Potassium | 299 | 93 |
| Metformin Hcl | Metformin Hcl | 273 | 76 |
| Montelukast Sodium | Montelukast Sodium | 270 | 93 |
| Gabapentin | Gabapentin | 263 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 262 | 62 |
| Glimepiride | Glimepiride | 243 | 70 |
| Furosemide | Furosemide | 237 | 89 |
| Carvedilol | Carvedilol | 218 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 64 |
| Allopurinol | Allopurinol | 191 | 52 |
| Tramadol Hcl | Tramadol Hcl | 186 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 56 |
| Potassium Chloride | Potassium Chloride | 174 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 58 |
| Chlorthalidone | Chlorthalidone | 170 | 40 |
| Prednisone | Prednisone | 169 | 86 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 47 |
| Simvastatin | Simvastatin | 138 | 47 |
| Valsartan | Valsartan | 135 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 40 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 113 | 47 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 112 | 31 |
| Trazodone Hcl | Trazodone Hcl | 108 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 27 |
| Meloxicam | Meloxicam | 103 | 35 |
| Spironolactone | Spironolactone | 94 | 30 |
| Azithromycin | Azithromycin | 93 | 77 |
| Alprazolam | Alprazolam | 91 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 24 |
| Farxiga | Dapagliflozin Propanediol | 83 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 28 |
| Eliquis | Apixaban | 80 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 21 |
| Famotidine | Famotidine | 73 | 21 |
| Benazepril Hcl | Benazepril Hcl | 66 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 17 |
| Digoxin | Digoxin | 63 | 15 |
| Finasteride | Finasteride | 63 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 62 | 21 |
| Buspirone Hcl | Buspirone Hcl | 60 | 17 |
| Ibuprofen | Ibuprofen | 60 | 36 |
| Novolin N | Insulin Nph Human Isophane | 60 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 48 |
| Glipizide | Glipizide | 57 | 18 |
| Ezetimibe | Ezetimibe | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 24 |
| Alendronate Sodium | Alendronate Sodium | 53 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 37 |
| Meclizine Hcl | Meclizine Hcl | 45 | 16 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | 12 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 11 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 22 |
| Jardiance | Empagliflozin | 39 | 12 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Benzonatate | Benzonatate | 33 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 25 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Bupropion Hcl | Bupropion Hcl | 31 | 20 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 30 | 13 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Novolin R | Insulin Regular, Human | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | 11 |
| Contrave | Naltrexone Hcl/Bupropion Hcl | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Repaglinide | Repaglinide | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $689.55 · 26 records | Abbott Laboratories | ABRYSVO, AVEIR, COMIRNATY, Cologuard Collection Kit, ELIQUIS, Extended Holter, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PRECIVITYAD2, PREVNAR 20, QUTENZA, REPATHA, SAPIEN 3 Ultra RESILIA, SCOPIS ENT, TRELEGY ELLIPTA, VRAYLAR, Veltassa, WATCHMAN FLX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error